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Abstract
CYP26A1, a cytochrome P450 enzyme, metabolizes all-trans-retinoic acid (RA) into polar metabolites, e.g. 4-oxo-RA and 4-OH-RA. To
determine if altering RA metabolism affects embryonic stem (ES) cell differentiation, we disrupted both alleles of Cyp26a1 by homologous
recombination. CYP26a1−/− ES cells had a 11.0±3.2-fold higher intracellular RA concentration than Wt ES cells after RA treatment for 48 h. RA-
treated CYP26A1−/− ES cells exhibited 2–3 fold higher mRNA levels of Hoxa1, a primary RA target gene, than Wt ES cells. Despite increased
intracellular RA levels, CYP26a1−/− ES cells were more resistant than Wt ES cells to RA-induced proliferation arrest. Transcripts for parietal
endodermal differentiation markers, including laminin, J6(Hsp 47), and J31(SPARC, osteonectin) were expressed at lower levels in RA-treated
CYP26a1−/− ES cells, indicating that the lack of CYP26A1 activity inhibits RA-associated differentiation. Microarray analyses revealed that RA-
treated CYP26A1−/− ES cells exhibited lower mRNA levels than Wt ES cells for genes involved in differentiation, particularly in neural (Epha4,
Pmp22, Nrp1, Gap43, Ndn) and smooth muscle differentiation (Madh3, Nrp1, Tagln Calponin, Caldesmon1). In contrast, genes involved in the
stress response (e.g. Tlr2, Stk2, Fcgr2b, Bnip3, Pdk1) were expressed at higher levels in CYP26A1−/− than in Wt ES cells without RA.
Collectively, our results show that CYP26A1 activity regulates intracellular RA levels, cell proliferation, transcriptional regulation of primary RA
target genes, and ES cell differentiation to parietal endoderm.
© 2007 Elsevier Inc. All rights reserved.Keywords: Retinoic acid; Metabolism; Stem cells; Endoderm differentiation; Vitamin A; CYP26A1; Microarray; Knockout; Cytochrome P450; ReviewIntroduction
Retinoids, a group of natural and synthetic analogs of retinol
(vitamin A), play essential roles during embryogenesis and have
profound effects on biological processes, such as cell
differentiation, cell proliferation, and cell death (Blomhoff
and Blomhoff, 2006; Mark et al., 2006). The biological effects
of retinoid signaling are primarily mediated through retinoic
acid receptors (RARs) and retinoid X receptors (RXRs),
members of the nuclear receptor superfamily that act as
ligand-inducible transcription factors (Ahuja et al., 2003;
Bastien and Rochette-Egly, 2004; Mark et al., 2006; Mongan
and Gudas, 2007). All-trans-retinoic acid (RA), the most potent
retinoid, binds and activates RARs, and 9-cis-RA binds and
activates both RARs and RXRs (Bastien and Rochette-Egly,⁎ Corresponding author. Fax: +1 212 746 8858.
E-mail address: ljgudas@med.cornell.edu (L.J. Gudas).
0012-1606/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2007.12.0212004). RXR–RAR heterodimers bind to the RA response
elements (RAREs) located in the promoter or enhancer regions
of target genes, and upon ligand binding, the receptors activate
transcription of the target genes (Bastien and Rochette-Egly,
2004; Gillespie and Gudas, 2007a,b; Su and Gudas, in press).
The metabolism of retinol (ROL) into its bioactive
derivatives, including RA, is mediated by different enzymes
(Blomhoff and Blomhoff, 2006). Cytochrome P450 RA
hydroxylase (CYP26), a family of cytochrome P450 enzymes
which has three known members in mammals (CYP26A1, B1,
and C1), is responsible for the oxidization of ROL and RA into
more polar metabolites (Abu-Abed et al., 2002; Lane et al.,
1999, 2008; MacLean et al., 2001; Reijntjes et al., 2003;
Tahayato et al., 2003; Taimi et al., 2004; White et al., 1997).
CYP26A1 was the first identified CYP26 member and was
cloned in zebrafish (White et al., 1996), mouse (Genbank No.
NM_007811), and human (Genbank No. NM_000783) (Fujii et
al., 1997; Lee et al., 2007; Ray et al., 1997; White et al., 1997).
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RAREs in its promoter region (Loudig et al., 2005). The
transcriptional activation of Cyp26a1 by RA acts to regulate
RA levels (Abu-Abed et al., 1998; Liu and Gudas, 2005; White
et al., 1997). Polar RA metabolites generated by CYP26A1
include 4-oxo-RA, 4-OH-RA, 18-OH-RA and other more polar
products (Chithalen et al., 2002; White et al., 1997).
All three CYP26s are expressed during murine embryonic
development in various tissues, with some spatial and temporal
differences. Cyp26a1 is expressed at the anterior end of the
embryo, and also in the tail bud and hindgut at the posterior end
of the embryo (Abu-Abed et al., 2002; de Roos et al., 1999;
MacLean et al., 2001; Reijntjes et al., 2004; Swindell et al.,
1999). Differential expression is seen in the branchial arches,
with Cyp26a1 mainly expressed in neural crest-derived
mesenchyme, Cyp26b1 in specific ectodermal and endodermal
areas (MacLean et al., 2007), and Cyp26c1 in the rostral portion
(Abu-Abed et al., 2002; MacLean et al., 2001; Reijntjes et al.,
2003; Tahayato et al., 2003). All three Cyp26 transcripts have
been detected in the hindbrain (MacLean et al., 2001; Tahayato
et al., 2003). Cyp26c1 is also expressed in the inner ear and
tooth buds of the mouse (Tahayato et al., 2003). Since the
expression patterns of the three Cyp26 genes are generally non-
overlapping, each enzyme most likely has an individual role in
RA metabolism during embryogenesis.
During embryonic development, precise levels of retinoids
must be generated in different developing structures at different
times. Inadequate levels of retinoids during embryonic devel-
opment result in a phenotype termed vitamin A deficiency
syndrome, which includes defects in the heart, brain, urogenital
and respiratory systems, and in the development of the skeleton
and limbs (Clagett-Dame and DeLuca, 2002; Means and Gudas,
1995; Zile, 2001). However, excess RA during murine
embryogenesis, as a result of the disruption of the Cyp26a1
gene, also causes many developmental defects, including caudal
truncation, abnormal patterning of the hindbrain, posterior
transformation of the cervical vertebrae, and defects in the
urogenital system (Abu-Abed et al., 2001; Sakai et al., 2001).
The major morphogenetic phenotypes resulting from the
disruption of CYP26A1 point to the importance of precisely
regulating retinoid levels during embryonic development for
appropriate retinoid signaling.
P19 embryonal carcinoma (EC) cells that stably overexpress
exogenously transfected Cyp26a1 were generated, and these
studies provided some insights into how CYP26A1 activity
affects cell differentiation (Sonneveld et al., 1999a). The P19
EC cells which overexpress Cyp26a1 differentiated into
neurons with low RA (1×10−8 M) treatment, unlike Wt P19
EC cells, and inhibition of CYP26A1 by the cytochrome P450
inhibitor, liarozole, was sufficient to inhibit this differentiation.
These data suggested that the increased expression of Cyp26a1
and the subsequent generation of a higher concentration of polar
RA metabolites caused neuronal differentiation of P19 EC cells
(Sonneveld et al., 1999a).
These data prompted us to examine the role of Cyp26a1
in the differentiation of murine embryonic stem (ES) cells.
ES cells are capable of self-renewal and have the ability todifferentiate into all cell types of the three germ layers. This
unique characteristic makes ES cells an ideal cell culture model
for investigating the mechanisms that control retinoid metabo-
lism, retinoid signaling pathways, and cell differentiation in
early embryonic development (Burdon et al., 2002; Gudas,
1994; Wobus and Boheler, 2005). Furthermore, the directed
differentiation of ES cells in culture is extensively being studied
and optimized for the use of ES cells as a cell transplant source
(Wobus and Boheler, 2005). Many directed differentiation
protocols use RA as a differentiating agent, so dissecting the
molecular pathways activated during RA-induced cell differ-
entiation is critical for understanding the molecular decisions
that result in differentiation. Our hypothesis is that disruption of
CYP26A1 activity would result in increased intracellular RA
levels, increased sensitivity to RA-induced proliferation arrest,
and increased transcription of RA-inducible genes. We
generated ES cell lines with both alleles of the Cyp26a1 gene
disrupted by homologous recombination to use as a model
system in which to characterize in detail the effects of RA
metabolism on ES cell proliferation, gene expression, and
differentiation.
Materials and methods
Cell culture and chemicals
AB1 murine ES cells, cultured in monolayer on gelatin-coated culture
dishes, were maintained as described in (Chen and Gudas, 1996). 1×103 units/
ml leukemia inhibitory factor (LIF) (Millipore-Chemicon LIF2010, Temecula,
CA) was added prior to use. All-trans-retinoic acid (Sigma Chemicals Co., St.
Louis, MO) and 4-oxo-RA (Hoffman-LaRoche, Nutley, NJ) were dissolved in
100% ethanol and diluted in ES medium to obtain final concentrations of
1×10−9–5×10−6 M. [3H]RA and [α-32P]dCTP were obtained from DuPont
NEN (Boston, MA). All experiments involving retinoids were performed in dim
light.
For cell proliferation studies, ES cells were plated on 12-well plates at a
density of 1×103/well for the cell doubling experiments and 1×104/well for the
RA-dose response experiments. For the cell doubling experiments, cells were
counted 96 h after plating using an electron particle counter (model: Coulter Z;
Beckman Coulter, Inc., Fullerton, CA). For the RA-dose response study, various
doses of RA (1×10−7 to 5×10−6 M) were added to the medium 24 h after
plating. Cells were cultured in the presence of RA for either 6 h and replenished
with ES medium without retinoids or for 72 h with a medium change after 48 h.
Control cells were treated with 0.1% ethanol (vehicle). Cells were counted using
an electron particle counter. Each experiment was performed in triplicate and the
entire experiment was repeated three times.
Generation of CYP26A1−/− ES cell lines
The murine Cyp26a1 targeting construct was a generous gift from Dr.
Martin Petkovich (Abu-Abed et al., 2001). The targeting construct is flanked by
2.8 kb of 5′ homology and 4.3 kb of 3′ homology, and contains a Cyp26a1
genomic sequence with a loxP site in intron 1 that is preceded by a novel BglII
restriction site, and a PGK-neomycin cassette in intron 6 that is flanked by loxP
sites (Fig. 1A). The EcoRI-linearized targeting construct was introduced into
AB1 ES cells by electroporation using the BioRad GenePulser Xcell (BioRad
Laboratories, Hercules, CA) at a voltage of 240 mV and capacitance of 500
microfarads. Positive colonies were isolated with G418 selection (300 μg/ml
active G418) and expanded. A total of 122 cell colonies were screened, and 2
positive cell lines were obtained. The cell lines that had undergone homologous
recombination were identified by Southern blot analysis with Probe 1 (Fig. 1B).
Genomic DNAwas digested with BglII for Southern blot analysis. The two cell
lines were expanded in the presence of 6 mg/ml active G418 to select for cell
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screened, and one positive cell line was determined to have both alleles replaced
by the targeting construct by Southern blot analysis with Probe 1 (Fig. 1C). The
cell line was expanded and transiently transfected with a Cre expression vector
(pBS185, Invitrogen #10347-011, Carlsbad, CA). Cre expression that resulted
in the removal of Cyp26a1 exons 2–6 and the neo/loxP cassette was determined
by Southern blot analysis with Probes 2 and 3 (Figs. 1D and E). Of 216 colonies
screened, 6 cell lines were positive.
DNA probes for Southern blot and Northern blot analyses
To confirm homologous recombination of the targeting construct, a 1 kb
DNA fragment (Probe 1 in Fig. 1A) that is outside of the construct (4.1 kb
upstream of the Cyp26a1 start site) was amplified from genomic DNA from
AB1 Wt ES cells with the forward primer, 5′-ACA CCG CAG TGG AGA
AGA-3′, and the reverse primer, 5′-GAA GGC AGATGATAG TGG CT-3′. A
310 bp DNA fragment that is part of exon 7 of the Cyp26a1 gene (Probe 2) was
amplified from genomic DNA from AB1 Wt ES cells using the forward primer,
5′-AGG GAT ACC AGA TCC CCA AG-3′ and the reverse primer, 5′-GGG
AGA TTG TCC ACA GGG TA-3′. The 609 bp cDNA fragment containing
Cyp26a1 exons 2–4 (Probe 3) was prepared by digesting a plasmid containingFig. 1. Generation of CYP26A1−/− ES cells lines by targeted excision of exons 2–6 of
of the Cyp26a1 wild-type locus (WT, top), targeting construct (middle), targeted alle
from Abu-Abed et al., 2001). The numbered boxes represent the seven exons of Cyp2
by 2.8 kb of 5′ homology and 4.3 kb of 3′ homology and contains novel BglII restr
resistance cassette in introns 1 and 6, respectively. Cre recombinase was introduced
neomycin resistance cassette. Southern blot analyses of genomic DNA digested with
excision of exons 2–6 and the PGK-neomycin resistance cassette. E: EcoRI restriction
of the two clones with one targeting construct (KO) in one allele and with theWT (+) C
which is outside the construct on the 5′ side. WT ES cells exhibited a 6.2 kb band,
heterozygous clone (+/KO) had both the 6.2 kb and 4.7 kb signal. (C) A colony (K
targeting construct, resulting in a single band at 4.7 kb after hybridization with Pro
individual colonies were picked and expanded for Southern blot analysis. (D) Probe 2
a 3.5 kb band, KO/KO yielded a 3.9 kb band due to the inclusion of the PGK-neomy
removal of exons 2–6 and the neomycin resistance cassette. This Southern blot is a rep
6 and the PGK-neomycin cassette. (E) Using Probe 3, which hybridizes to Cyp26a1
observed in the KO/KO ES cells, and no signal was detected in the CYP26A1−/− ES c
lines that lacked both exons 2–6 and the PGK-neomycin cassette. (F) Total RNAwas
lines treated with 1 μMRA or control vehicle (C) for 24 h for Northern blot analysis.
ES cells only. All three RA treated CYP26A1−/− ES cell lines had a signal at ∼700the full-length Cyp26a1 cDNA in pBluescript vector with PstI (New England
Biolabs).
The following cDNA probes were used in the Northern blot assays: Hoxa1
(Genbank No. NM_010449) inserted into the EcoRI site of the pUC-9 vector
(LaRosa and Gudas, 1988). LamA1 (Genbank No. NM_008480) was obtained
from Dr. Y. Yamada (Sasaki et al., 1988). LamB1 (Genbank No. NM_008482),
LamC1 (Genbank No. NM_010683), J31 (Genbank No. NM_009242; also
known as SPARC and osteonectin), and J6 (Genbank No. NM_009825; also
known as Hsp47 and Serpinh2) cDNAs were originally cloned from a F9 EC cell
cDNA library in our laboratory (Wang and Gudas, 1983; Wang et al., 1985).
Retinoid extraction and high performance liquid chromatography
(HPLC) analysis
Cells were seeded in 60 mm tissue culture dishes at a density of 5×105 cells/
dish in ES medium with or without LIF. The next day, medium containing 1 μM
non-radiolabeled RA was added to the cells for 24 h. Then, the medium was
replaced with medium containing 50 nM [3H]RA for 8 h. In a different
experiment, 24 h after seeding cells, medium containing 100 nM [3H]RA was
added to the cells for 8 h. The following steps were the same for both
experiments. A separate control consisting of radiolabeled RA in mediumthe Cyp26a1 gene by homologous recombination. (A) Schematic representations
le (KO, middle), and null allele (Cyp26a1−/−, bottom) are shown here (modified
6a1. The targeting construct contains the genomic sequence of Cyp26a1 flanked
iction sites preceding the subcloned loxP sites (triangles) and a PGK-neomycin
to excise at the loxP sites, resulting in the removal of exons 2–6 and the PGK-
BglII, using three different probes, determined homologous recombination and
site and B: BglII restriction site. (B) This blot is a representative example of one
yp26a1 locus in the other allele. The Southern blot was hybridized with Probe 1,
while the cell lines with the targeting construct exhibited a band at 4.7 kb. The
O/KO) was found to have both Cyp26a1 alleles replaced (Cyp26a1Δ) by the
be 1. The KO/KO clone was electroporated with a Cre-expression vector, and
, which hybridizes to Cyp26a1 exon 7, was used. TheWT Cyp26a1 locus yielded
cin cassette, and the CYP26A1−/− clones yielded a 2.2 kb band as a result of the
resentative example of one of the six positive cell lines that lacked both exons 2–
exon 2–4, a 6.2 kb band was observed in the Wt ES cells, a 1.5 kb band was
ells. This Southern blot is a representative example of one of the six positive cell
extracted from AB1 WT ES cells and CYP26A1−/− #59, #142, and #165 ES cell
The 1.7 kb full-length Cyp26a1mRNAwas expressed after RA treatment in WT
bp, which corresponds to the size of exons 1 and 7.
Fig. 1 (continued).
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was collected and cells were scraped into PBS for extraction. Radiolabeled
retinoids were extracted from both cells and media under dim light at room
temperature. Non-radiolabeled retinoid standards were added to the samples
before extraction so that their elution profiles could be followed by absorbance.
Retinoids were extracted immediately as previously described by Guo and
Gudas (1998). The HPLC analysis was performed using a Waters Millennium
system (Waters Corp., Milford, MA) equipped with a photodiode array detector
to separate the various retinoids as previously described (Suh et al., 2006). Non-
radiolabeled retinoid standards in each sample were run concurrently and were
monitored at a wavelength of 340 nm while a Packard A-500 radiochromato-
graphy detector (Packard Instruments, Downers Grove, IL) was employed to
monitor the radiolabeled retinoids. The criteria used to identify all-trans-RA and
4-oxo-RA were coelution with known standards and UV spectral analysis of
peaks in this region of the chromatogram. The amounts of retinoids were
calculated on the basis of their peak areas, volume of the sample, concentration
of the starting [3H]all-trans-RA, and the total radioactive counts of the starting
[3H]all-trans-RA. The lower limit of detection, calculated from standard
controls, is approximately 0.4 pmol.
Drug treatments for microarray analysis experiments
For the microarray analysis, three different conditions were tested in Wt
AB1 ES cells and CYP26A1−/− ES cells: Control (+LIF), 8 h; RA (+LIF), 8 h;
and RA (+LIF), 72 h. Cells were treated with 100 nM all-trans RA or 0.1%
ethanol (control vehicle) in the presence of LIF. Total RNAwas harvested from
the plates at 8 h and 72 h. Two conditions, Control (+LIF), 8 h and RA (+LIF),
8 h, were repeated independently, starting with freshly thawed cells, three times
in the microarray chips. One condition, RA (+LIF), 72 h, was repeated
independently two times.
Microarray analysis
Biotinylated cRNA targets were prepared using the One-Cycle cDNA
Synthesis Kit (Affymetrix P/N 900431, Santa Clara, CA) by following the
manufacturer's instructions. Briefly, double-stranded cDNA was synthesizedfrom 5 μg total RNA with Superscript II™ reverse transcriptase. After
purification, the cDNA was used as a template in the subsequent in vitro
transcription reaction for complementary RNA (cRNA) amplification and biotin
labeling. The biotinylated cRNA targets were fragmented and hybridized to the
GeneChip® Mouse Genome 430 2.0 arrays, which have 45,101 probe sets (each
with a unique Affymetrix Identifier) representing over 34,000 mouse genes
(Affymetrix 900496). The hybridization and subsequent scanning of the chips
were performed by the microarray core facility at Weill Cornell Medical
College.
Data from the chips were recorded as .cel files, which were directly imported
into the software program GeneSpring GX 7.3.1 (Redwood, CA) for
computational analysis. The data preprocessing method used was GC-RMA.
The normalization involved two sequential steps: (1) Data transformation of all
data less than 0.01 was reset to 0.01. (2) Each chip was normalized to 50th
percentile of the total intensity. After normalization, the data were filtered by
expression. Probe sets with expression values over 100 arbitrary units were
filtered by fold-change. Samples were compared, and the log ratio expression of
probe sets that had changed by 2-fold or more was statistically tested for
significance. Probe sets that passed these filters were studied further by RT-PCR
and bioinformatics analyses. Consultation on the analyses, including statistical
analysis, was done with Piali Mukherjee, a microarray analysis expert from the
Computational Genomics Core Facility at Weill Cornell Medical College.
All microarray data from this study have been submitted to the GEO
database (http://www.ncbi.nlm.nih.gov/geo/) and the Series accession number
will be released to the public, pending publication of this manuscript.
Semi-quantitative reverse transcription-polymerase chain reaction
(RT-PCR)
For the semi-quantitative RT-PCR analysis of differentially expressed genes,
Wt and CYP26A1−/− ES cells were plated on gelatin-coated, 10-cm tissue
culture plates, and treated with various concentrations of all-trans RA as
indicated. After various times of drug treatment, cells were harvested for total
RNA extraction. As a control, cells were treated with 0.1% ethanol (control
vehicle). Total RNA (5 μg) was reverse-transcribed with Superscript II
(Invitrogen) and primed with 1 μg of random hexanucleotides. Samples were
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amplified in the linear range by PCR using the following primers: 36B4, 448 bp
(upper primer, 5′-AGAACAACC CAG CTC TGGAGAAA -3′; lower primer,
5′-ACA CCC TCC AGA AAG CGA GAG-3′); Epha4, 202 bp (upper primer,
5′-TGG ATT CCA GAT CTG TTC AGG GAG-3′; lower primer, 5′-ATT TCA
ATG TAC ACC CTC TGC GCC-3′); Ltbp3, 281 bp (upper primer, 5′-AAC
ATG ACG CTC ATC GGA GAG AAC-3′; lower primer, 5′-TGT TTG CTA
GCC ACA GAC TCT CCT-3′); Tagln, 441 bp (upper primer, 5′-GCT GGA
GGAGCG ACTAGT GG-3′; lower primer, 5′-CCT CCT GCA GTT GGC TG-
3′); PrkWnk3, 995 bp (upper primer, 5′-GTG GAT CAT TTC AGC GG-3′;
lower primer, 5′-ATG GCA GGC TCC ACT TC-3′); Pmp22, 398 bp (upper
primer, 5′-ATA GCT GGT GGC TCC TGA ACA CTT-3′; lower primer, 5′-
ACA AGT CAT CGC CAG ACA GTC CTT-3′); Aass, 256 bp (upper primer,
5′-AGC TTC CAATCG AGG CTA CGG AAT-3′; lower primer, 5′-ACATAG
CCA GAC CCA AGG ACC AAA-3′); LamB1, 563 bp (upper primer, 5′-GAT
AAC TGT CAG CAC AAC ACC-3′; lower primer, 5′-GTG AAG TAG TAA
CCGGAC TCC-3′). The primers were designed to span two exons, and checked
for specificity to the gene and lack of hybridization to pseudogenes using the
University of California at Santa Cruz In-Silico PCR online program (http://
genome.ucsc.edu).
Gene ontology annotation and enrichment analysis in DAVID
Affymetrix Identifiers for genes that passed the filters in GeneSpring GX
7.3.1 (Redwood, CA) were uploaded into the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) software program (http://
niaid.abcc.ncifcrf.gov/) for functional annotation study. The functional annota-
tion clustering tool was used to sort genes according to their Gene Ontology
(GO) terms and to identify functional categories that were over-represented in a
gene list relative to the representation within the genome of a given species. The
species Mus musculus was selected for this study. Affymetrix Mouse 430 2.0
was chosen as the background. Genes with positive fold-changes and negative
fold-changes from each drug condition were analyzed separately in DAVID to
understand how up-regulated genes in Wt ES cells versus up-regulated genes in
CYP26A1−/− ES cells related to biological function in each of the two cell lines.
Statistical methods
The means±standard errors of the mean (S.E.M.) were calculated using
GraphPad Prism 4.0 software (San Diego, CA) and Microsoft Excel (Redmond,
WA). The Student's t-test was used to determine differences between two
groups, and the one-way analysis of variance was used to determine differences
among multiple experimental groups. Differences with a p-value of b0.05 were
considered to be statistically significant.Results
Generation of multiple, independent CYP26A1−/− ES cell lines
To address the biological functions of Cyp26a1 in ES cells,
both alleles of the Cyp26a1 gene were disrupted in AB1 Wt ES
cells by two rounds of homologous recombination. AB1 Wt ES
cells were transfected with a targeting construct containing the
Cyp26a1 genomic DNA with a loxP site in intron 1 that is
preceded by a novel BglII restriction site and a PGK-neomycin
resistance cassette in intron 6 that is flanked by loxP sites (Fig.
1A). Of 122 colonies screened by Southern blot analysis using
Probe 1, two colonies were found to have integrated the
targeting construct by homologous recombination (Fig. 1B).
These colonies were grown in 6 mg/ml G418 to select for
colonies that had two copies of the targeting construct. A total of
48 surviving colonies were picked and screened by Southern
blot analysis using Probe 1. One colony out of 48 was found tohave both Cyp26a1 alleles replaced by the targeting construct
(Fig. 1C). This colony (KO/KO or Cyp26Δ) was expanded and
then transiently transfected with a Cre expression vector by
electroporation. Cre recombinase expression that resulted in the
deletion of Cyp26a1 exons 2–6 as a result of the removal of the
neo cassette in the ES cells was determined by Southern blot
analysis using Probe 2 and Probe 3 (Figs. 1D and E). A total of
216 colonies were picked, and 6 colonies were found to lack
Cyp26a1 exons 2–6. These AB1 ES cell-derived cell lines
were named CYP26A1−/− #22, 59, 142, 165, 169, and 184.
The CYP26A1−/− #59, 142, and 165 ES cell lines were
tested for Cyp26a1 mRNA expression by Northern blot
analysis to confirm the absence of the Cyp26a1 message. The
CYP26A1−/− ES cells were treated with 1 μM RA for 24 h.
The Northern blot analysis results show that CYP26A1−/− ES
cells do not express the 1.7 kb, full-length Cyp26a1 mRNA
seen in Wt ES cells, but they do express a truncated transcript
of 0.7 kb, presumably containing exons 1 and 7, after RA
treatment (Fig. 1F). To confirm that the truncated transcript
did not contain any enzymatic activity, we assayed CYP26A1
enzyme activity by reverse-phase HPLC.
All-trans-RA metabolism in CYP26A1−/− ES cells cultured in
the presence of LIF
Two independent CYP26A1−/− ES cell lines, #59 and #142,
were tested by HPLC to examine RA metabolism. Wt,
CYP26A1−/− #59, and CYP26A1−/− #142 ES cells were
cultured in the presence of 1 μM non-radiolabeled RA for
24 h and then treated with 50 nM radiolabeled RA for 8 h. The
24-h treatment with the unlabeled RA was used to induce
expression of metabolic enzymes, i.e. CYP26A1, while the
radiolabeled RA was used to measure RA metabolism by
reverse-phase HPLC. The Wt ES cells exhibited high levels of
polar RA metabolites, while both CYP26A1−/− #59 and #142
ES cell lines did not show any radioactive counts above
background where RA metabolites elute, indicating that both
CYP26A1−/− #59 and #142 ES cell lines did not generate any
polar RA metabolites from RA (data not shown, but see below
for more detailed HPLC analyses). Thus, the removal of exons
2–6 resulted in an inactive CYP26A1 enzyme and the inability
of the CYP26A1−/− #59 and #142 cell lines to metabolize RA.
These experiments show that any protein translated from the
truncated transcript is not functional in the CYP26A1−/− ES
cells. In addition, these data demonstrate that there is no other
redundant enzyme that is actively metabolizing RA during the
time period tested.
We then assessed RA metabolism in AB1 Wt versus
CYP26A1−/− ES cells. Wt and CYP26A1−/− #59 ES cells
were cultured with 100 nM [3H]RA for 8, 24, and 48 h, either in
the presence or absence of LIF. LIF is a critical growth factor
that is added to the ES medium to maintain pluripotency of
murine ES cells; its absence promotes ES cell differentiation
spontaneously in cell culture (Boeuf et al., 1997).
RA treatment of Wt ES cells induced a rapid and efficient
metabolism of RA into polar RA metabolites after 8 h of RA
treatment, and by 48 h, all of the RA had been metabolized into
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Fig. 2. HPLC analysis showing RA and polar RA metabolites detected in WT and CYP26A1−/− #59 ES cells after culture with [3H]all-trans-RA for 8, 24, and 48 h.
Cells and media were harvested, retinoids extracted, and reverse-phase HPLC analysis was performed to separate the retinoids. Quantitative data from multiple
experiments are shown in panels E–H. (A) Non-radiolabeled retinoids were included in the HPLC analysis as standards to determine the retention times of the
various retinoids. The data were plotted as absorbance at 340 nm versus time in minutes. RA, all-trans-RA, 24 min; ROL, all-trans-retinol, 33 min; RP, retinyl
palmitate, 39 min; all-trans-4-oxo-RA, 10 min. (B) WT and CYP26A1−/− ES cells were cultured in the presence of [3H] all-trans-RA for 8 h. (C) WT and
CYP26A1−/− ES cells were cultured in the presence of [3H] all-trans-RA for 24 h. (D) WT and CYP26A1−/− ES cells were incubated with [3H] all-trans-RA for
48 h. To determine total RA or polar RA metabolite concentrations, we first calculated the sum of [3H] all-trans-RA or [3H]RA metabolites counts per minute in the
cells (E, G) and media (F, H) for each time point. Since the cell number, cell volume, medium volume, and concentration of the starting [3H] all-trans-RA were
known, total [3H]-retinoid counts could be converted to concentration (nM). The Student's t-test was used to determine statistically significant differences between
retinoid concentrations from WT and CYP26A1−/− ES cells or media at each time point with LIF (+L) or without LIF (−L). Statistical significance is denoted by
* (pb0.05), ** (pb0.01) and *** (pb0.0001).
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polar RA metabolites was not seen in the CYP26A1−/− #59 ES
cell line after 8 h of RA treatment (Fig. 2B). In CYP26A1−/− ES
cells cultured with LIF (+LIF), polar RA metabolites were not
detected until after 48 h of RA treatment (Fig. 2D). In addition,
the levels of intracellular RA, normalized to cell number, were
higher in the CYP26A1−/− cells than in the Wt cells at all times
tested (Fig. 2E). CYP26A1−/− ES cells (+LIF) had 2.0±0.5-
fold higher intracellular RA levels than Wt ES cells (+LIF) after
8 h RA treatment (pb0.05), 3.7±0.4-fold higher intracellular
RA levels after 24 h of RA treatment (pb0.05), and 11.0±3.2-
fold higher intracellular RA levels after 48 h of RA treatment
(pb0.05, Fig. 2E). These data prove that CYP26A1 is the major
and only enzyme responsible for metabolizing RA into polar
RA metabolites in murine ES cells during the first 48 h of RA
treatment.
Higher levels of polar RA metabolites were found in the Wt
ES cells than in the CYP26A1−/− ES cells at all times tested(Figs. 2G and H). Wt ES cells (+LIF) exhibited an average
intracellular RA polar metabolite (sum of all metabolites)
concentration of 670±251 nM after 8 h, 671±166 nM after
24 h, and 500±68 nM after 48 h of RA treatment. The
concentration of all polar RA metabolites does not increase over
time because these polar RA metabolites are excreted from the
cells and/or further metabolized by CYP26A1 to compounds
not extracted by acetonitrile/butanol (Chen and Gudas, 1996;
Chithalen et al., 2002). After 8 and 24 h of RA treatment,
CYP26A1−/− ES cells (+LIF) exhibited no radioactive counts
above background where polar RA metabolites normally elute;
therefore, polar RA metabolites were not detected in
CYP26A1−/− ES cells after 8 and 24 h of RA treatment. After
48 h of RA treatment, CYP26A1−/− ES cells (+LIF) exhibited
an average intracellular RA polar metabolite concentration of
119.8±10 nM, which is approximately 20% of the level in Wt
ES cells at the same time point (Fig. 2G). We do not know what
enzyme is producing the polar metabolites in the CYP26A1−/−
Fig. 3. Effect of varying doses of all-trans-RA on the proliferation of WT and
CYP26A1−/− #59 ES cells. The AB1 ES cell lines were grown in ES medium
(+LIF) with varying RA concentrations (0–5 μM) for 6 or 72 h. Cells treated for
6 h only were rinsed with medium to remove residual retinoids and replenished
with normal ES medium without RA for the remainder of the experiment. 72 h
after the initial RA treatment, cells were counted, and the ratio of proliferation
was calculated by comparing the drug treated group to the same cell line without
RA treatment. The data are from three independent experiments, and each
sample was counted in triplicate. The Student's t-test was used to determine
statistical differences between Wt and CYP26A1−/− ES cells. Cell proliferation
was statistically different betweenWt and CYP26A1−/− ES cells treated with RA
for 72 h (***pb0.001) and for 6 h (**pb0.01). Differences between the 72 h
and 6 h RA treatments also reached statistical significance for WT (**pb0.01)
and for CYP26A1−/− ES cells (*pb0.05).
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expressed at similar levels in both Wt and CYP26A1−/− ES cells
after RA treatment for 72 h, so it is possible that CYP26B1
activity is responsible for the metabolism of RA at the later time
points (data not shown). Thus, we conclude that: a) during the
first 48 h in the presence of 100 nM RA +LIF the CYP26A1−/−
ES cells do not metabolize RA, and b) the intracellular RA
concentration is several fold higher in RA treated CYP26A1−/−
ES cells than in Wt ES cells.
All- trans-RA metabolism in CYP26A1−/− ES cells cultured in
the absence of LIF
As compared to culture in the presence of LIF, Wt ES cells
cultured in the absence of LIF exhibited 43% and 10%
increases in RA metabolism at 8 and 24 h after RA treatment,
respectively, as calculated by the total amounts of polar RA
metabolites detected in the cell extracts and medium (Figs. 2G
and H). By 48 h, nearly all of the RAwas metabolized in Wt ES
cells cultured in either the presence or absence of LIF (Figs. 2E
and F). Low levels of polar metabolites of RAwere detected in
the cell extracts (206 nM±43.5) and in the media (4.2±0.1 nM)
of CYP26A1−/− cells cultured without LIF, but not in the cell
extracts or in the media of these cells cultured with LIF at the
24-h time point (Figs. 2G and H). After 48 h of RA treatment,
low levels of polar RA metabolites were detected in cell extracts
(119.8±10 nM, +LIF; 151.3±4.2 nM, −LIF) and in the media
(7.4±1.5 nM, +LIF; 27.6±9.8 nM, −LIF) of CYP26A1−/− ES
cells cultured with or without LIF (Figs. 2G and H). We
conclude that the absence of LIF increases RA metabolism in
both Wt and CYP26A1−/− ES cells in a CYP26A1-independent
manner.
Cell proliferation of Wt and CYP26A1−/− ES cells
To determine whether disrupting Cyp26a1 affects ES cell
proliferation, we measured the cell proliferation rates of two
CYP26A1−/− ES cell lines, #59 and #142, compared to Wt ES
cells. Wt ES cells doubled in 14.67±2.85 h (mean±range).
CYP26A1−/− #59 and #142 ES cells doubled in 13.76±2.2 h
and 12.27±1.15 h, respectively. The population doubling rates
among all three ES cell lines were not statistically different,
showing that the disruption of both alleles of Cyp26a1 did not
affect ES cell proliferation in normal ES medium containing
LIF.
RA inhibits proliferation of various cell types, including
murine ES cells (Martinez-Ceballos et al., 2005). Since the
CYP26A1−/− ES cells had higher intracellular levels of RA than
the Wt ES cells after RA treatment (Fig. 2), we wanted to
determine how RA treatment would affect proliferation of these
cells. Wt and CYP26A1−/− #59 ES cells were treated with
varying concentrations (1×10−9 to 5×10−6 M) of RA for 72 h
and counted. Like Wt ES cells, the CYP26A1−/− ES cells were
growth inhibited by RA treatment in a dose-dependent manner
(Fig. 3). However, the CYP26A1−/− ES cells were growth
inhibited to a lesser degree than AB1 Wt ES cells at the same
doses of RA, indicating that the CYP26A1−/− ES cell lines weremore resistant to growth inhibition by RA than Wt ES cells
(Fig. 3). To investigate whether short treatments of RA were
sufficient for growth arrest we cultured ES cells with RA for
6 h and then replenished with fresh medium without RA for
the remainder of the experiment. We observed that in Wt cells,
72 h of RA treatment was more effective in inhibiting
proliferation than 6 h of RA treatment (Fig. 3). However, in the
CYP26A1−/− ES cells the 6- and 72-h RA treatments resulted
in similar degrees of growth inhibition (Fig. 3), suggesting that
the metabolism of RA by CYP26A1 in Wt ES cells over time
contributed to the proliferation arrest.
Hoxa1 mRNA expression
Northern blot analysis was performed to determine if the
disruption of the Cyp26a1 gene would affect transcription of the
direct RA target gene, Hoxa1. Hoxa1 has a DR5 RARE in the
3′ enhancer, which is required for transcriptional activation by
RA (Boylan et al., 1993; Langston and Gudas, 1992; Langston
et al., 1997; LaRosa and Gudas, 1988). Since the CYP26A1−/−
ES cells have higher intracellular RA levels (Fig. 2), we
expected to observe higher expression of Hoxa1 mRNA in the
CYP26A1−/− ES cells. At both the 24- and 72-h time points, the
Hoxa1 gene was transcriptionally activated in an RA dose-
dependent manner in both Wt and CYP26A1−/− ES cell lines,
but was expressed at 3.65±1.39 and 1.97±0.31-fold higher
levels in CYP26A1−/− ES cells than in Wt ES cells treated with
1 and 100 nM RA, respectively, for 72 h (Fig. 4).
We also included the KO/KO cell line in our analyses (Fig.
1D). This cell line has both of the “floxed” Cyp26a1 alleles in it,
Fig. 4. Northern blot analysis of Hoxa1 mRNA levels. All Hoxa1 mRNA levels
were normalized to GAPDH mRNA levels to control for loading. (A) A
representative Northern blot showing Hoxa1 mRNA in WT, CYP26A1−/− #59,
and CYP26A1−/− #142 after varying RA doses (0–1000 nM) for 24 h. (B) WT
ES cells and CYP26A1−/− #59 ES cells were treated with varying RA doses (0–
1000 nM) for 24 h. The y-axis is Hoxa1/GAPDH mRNA levels, quantitated by
Phosphorimager analysis, for each CYP26A1−/− sample compared to Hoxa1/
GAPDH mRNA for WT ES cells treated with 100 nM RA. The differences in
mRNA levels among the WT ES cells and CYP26A1−/− ES cell lines were
statistically significant for the 1 nM RA treatment (pb0.05), but the differences
in mRNA levels among the cell lines were not statistically significant at 100 nM
RA (p=0.6372). The data point for the 1000 nM RA treatment is from one
experiment. (C) WT ES cells and CYP26A1−/− #59 ES cells were treated with
varying RA doses (0–1000 nM) for 72 h. The differences in mRNA levels
between WT ES cells and CYP26A1−/− ES cells were statistically significant at
1 nM and at 100 nM RA treatment (pb0.05). Statistical significance is indicated
by a * (pb0.05).
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the neomycin resistance gene and exons 2 through 6. This KO/
KO cell line behaved like the J1 Wt cells, as expected, with
respect to Hoxa1 mRNA levels induced by RA (data not
shown). Thus, these data show that the increased intracellular
RA levels seen in the CYP26A1−/− ES cells (Fig. 2) are active in
the nucleus, where RA binds to RXR–RARγ heterodimers to
activate Hoxa1 gene transcription to a greater extent.Differentiation specific gene expression
Our laboratory isolated cDNA clones for several RA
regulated, differentiation-specific “late-response” genes,
LamB1, J6, and J31, from RA-treated F9 Wt EC cells, and
characterized their expression profiles (Chen and Gudas, 1996;
Wang and Gudas, 1988; Wang et al., 1985). These genes exhibit
steady state mRNA levels that can be detected approximately
24 h after RA treatment and that reach maximal levels around
48 to 72 h after RA treatment (Wang et al., 1985). Both RNA
synthesis and protein synthesis were shown to be required for
the induction of these genes by RA, indicating that RA
regulation of these genes is indirect (Wang and Gudas, 1988;
Wang et al., 1985). LamB1 is a gene that encodes the laminin
β1 chain, a glycoprotein that is a major constituent of the
extracellular matrix (Ekblom et al., 2003). Our laboratory had
previously described cis-acting DNA regulatory elements,
including an RARE, that regulate tissue-specific LamB1
expression (Li and Gudas, 1997; Sharif et al., 2001; Vasios et
al., 1991, 1989). LamB1 mRNA expression was 5.4±1.4-fold,
4.8±0.3-fold, and 1.8±0.2-fold higher in RA-treated Wt ES
cells than in CYP26A1−/− ES cells at 24, 48, and 72 h,
respectively (Fig. 5B). The basal level of LamB1 mRNA was
also reduced in CYP26A1−/− ES cells (Fig. 5C). Culturing Wt
and CYP26A1−/− ES cells with increasing concentrations of RA
activated transcription of LamB1 in a dose–responsive manner,
but the LamB1 mRNA levels were higher in Wt than in
CYP26A1−/− ES cells at all RA concentrations (Fig. 5C). These
results show that the lack of CYP26A1 activity is associated
with a reduction in LamB1 mRNA levels. Culture in the
presence of the polar RA metabolite, 4-oxo-RA, increased
LamB1 mRNA levels in both Wt and CYP26A1−/− ES cells.
However, 4-oxo-RAwas less potent than RA at a similar dose in
both Wt and CYP26A1−/− ES cells (Fig. 5D), indicating that the
reduced LamB1 mRNA levels seen in RA-treated CYP26A1−/−
ES cells did not result from the absence of the polar RA
metabolite, 4-oxo-RA. Next, we cultured CYP26A1−/− ES cells
in the presence of both RA and 4-oxo-RA to determine if
treating with both retinoids would restore LamB1 mRNA levels
in CYP26A1−/− ES cells to those of Wt ES cells, but co-
treatment did not increase LamB1mRNA levels in CYP26A1−/−
ES cells to those of Wt ES cells (data not shown).
We also examined LamA1 and LamC1, other members of the
laminin family, which encode the laminin α1 chain and the
laminin γ1 chain, respectively (Aberdam et al., 2000; Ekblom et
al., 2003). LamA1 mRNA levels were 1.4±0.03-fold higher in
100 nM RA-treated Wt ES cells than in 100 nM RA-treated
CYP26A1−/− ES cells (Fig. 5E). Culture in the presence of 4-
oxo-RA increased LamA1 mRNA levels in both Wt and
CYP26A1−/− ES cells, but 4-oxo-RA was less potent than RA
(data not shown). LamC1 mRNA levels were 1.1±0.01-fold
higher in RA-treated Wt ES cells than in RA-treated
CYP26A1−/− ES cells (data not shown). These data show that
CYP26A1 is important for the appropriate increases in LamA1,
LamB1, and LamC1 mRNA levels.
J31 and J6 are two other RA-inducible genes that were
isolated from RA-treated F9 EC cells and they show expression
Fig. 5. Northern blot analyses of LamB1 and LamA1 mRNA levels. (A) A representative blot showing LamB1 mRNA levels in WT and CYP26A1−/− #59 ES cells
after treatment with either RA (1 or 100 nM) or 4-oxo-RA (1 or 100 nM) for 72 h. (B) LamB1 mRNA levels after 100 nM RA treatment of WT ES and CYP26A1−/−
#59 ES cells for 24, 48, and 72 h. The y-axis is the relative LamB1/GAPDH mRNA levels for each sample compared to the LamB1/GAPDH mRNA level for WT ES
cells treated with 100 nM RA for 24 h. The differences in mRNA levels between WT ES cells and CYP26A1−/− ES cells were statistically significant (*) at all three
time-points tested (pb0.05). (C) LamB1mRNA levels after 72 h treatment with varying doses of RA (0–1000 nM). Statistically significant (pb0.05) values are shown
by *. (D) LamB1mRNA levels after 72 h treatment with 100 nM RA or 100 nM 4-oxo-RA. LamB1mRNA levels for WT ES cells were statistically different (*) from
those for CYP26A1−/− ES cells. (pb0.05 for each drug treatment). (E) LamA1 mRNA levels after 72 h treatment with varying doses of RA (0–1000 nM). The
differences in mRNA levels between WT and CYP26A1−/− ES cells were statistically significant (*) for all concentrations of RA tested (pb0.05). In most cases,
symbol points were larger than the S.E.M.
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sequence was found to be identical to the gene, secreted protein
acidic and rich in cysteine (SPARC, also known as osteonectin)
(Mason et al., 1986). RA treatment of both Wt and
CYP26A1−/− ES cells increased J31 mRNA levels in a dose-
dependent manner, but the mRNA levels were 1.54±0.04-fold
higher in 100 nM RA-treated Wt as compared to 100 nM RA-
treated CYP26A1−/− ES cells (Fig. 6A). J6 encodes a gene for
a heat shock protein, HSP47, that is involved in collagen
biosynthesis (Bielinska and Wilson, 1995; Clarke et al., 1991;
Henle et al., 1994). The carboxy-terminal portion has sequencesimilarity to members of the serpin (serine protease inhibitor)
family, but the molecule does not possess protease inhibitor
activity (Wang and Gudas, 1990). J6 mRNA was increased by
100 nM RA in both Wt and CYP26A1−/− ES cells, but the J6
mRNA levels were 1.49±0.04-fold higher in Wt ES cells than
in CYP26A1−/− ES cells (Fig. 6B).
In addition, while the gene expression profiles for RA-
inducible genes were very similar in Wt and CYP26A1−/− ES
cells, other molecular markers of parietal endoderm, including
tissue plasminogen activator, GATA-4, and parathyroid hor-
mone receptor, were expressed at 3–5 fold higher levels in
Fig. 6. Northern blot analyses of J31 and J6 genes. (A) J31mRNA levels after 72 h treatment with varying doses of RA (0–1000 nM). The y-axis shows J31/GAPDH
mRNA levels for each sample compared to the J31/GAPDH mRNA levels for the WT ES cells control sample. The differences in the mRNA levels between WT and
CYP26A1−/− ES cell after RA treatment at 0, 100, and 1000 nM were statistically significant (pb0.05). In most cases, symbol points were larger than the S.E.M. (B)
J6 expression after 72 h treatment with varying doses of RA (0–1000 nM). The differences in the mRNA levels between WT and CYP26A1−/− ES cell after RA
treatment at 1, 100, and 1000 nM were statistically significant (pb0.05). In most cases, symbol points were larger than the S.E.M. Statistical significance is indicated
by * (pb0.05).
Fig. 7. Design of microarray experiment and analysis of differentially expressed
genes. (A) Three drug conditions were used to examine gene expression in WT
and CYP26A1−/− ES cells. A “#” indicates the number of times the microarray
analysis was performed, starting with fresh cells. (B) Genes had to pass three
filters to be considered differentially expressed between WT and CYP26A1−/−
ES cells. Beginning with all Affymetrix Ids on the Mouse 430 2.0 GeneChip
(45,101 probe sets), the first filter removed probes with raw expression less than
100 arbitrary units. The second step filtered out probes with less than a 2-fold
difference in expression between WT and CYP26A1−/− ES cells. The third step
filtered out statistically insignificant means based on the Student's t-test
(pN0.05). The remaining probes were considered to be genes with a 2-fold or
greater difference in expression between WT and CYP26A1−/− ES cells and the
top 20 and bottom 20 transcripts are listed in Tables 1–3.
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after RA addition in the presence of LIF (data not shown).
Collectively, our data show that the genes expressed in response
to RA at later times (e.g. 72 h) in the differentiated parietal
endoderm cells, such as the laminin genes, are induced to a
lesser extent in the CYP26A1−/− ES cells. These lower mRNA
levels in the CYP26A1−/− ES cells indicate that differentiation
of ES stem cells to parietal endoderm is reduced by the lack of
CYP26A1 activity.
Identification of genes differentially expressed in response to
RA in Wt ES cells versus CYP26A1−/− ES cells by microarray
analyses
Next, we performed microarray analyses using the Affyme-
trix GeneChip Mouse 430 2.0 arrays, which are genome-wide
arrays with 45,101 unique probe sets representing transcripts
and variants for over 34,000 mouse genes. Three conditions
were used to examine AB1 Wt and CYP26A1−/− #59 gene
expression patterns: (A) Control vehicle for 8 h, (B) 100 nM RA
for 8 h, and (C) 100 nM RA for 72 h (Fig. 7A), as described in
Materials and methods. The data were imported into the
software program GeneSpring GX 7.3.1 (Redwood, CA) for
analyses.
To identify genes that are either up-regulated or down-
regulated in the Wt versus CYP26A1−/− ES cells, three
independent analysis steps were taken for each condition (Fig.
7B). Each of the 45,101 unique probe sets on the microarray
chips were analyzed individually, even though some genes had
multiple probe sets. First, probe sets with low expression (less
than 100 arbitrary units of raw data) in samples from both Wt
and CYP26A1−/− ES cells were filtered out because genes with
background expression levels are not reliable for calculating
fold-change due to exaggerated ratios. In Condition A, Control
for 8 h, 14,703 probe sets passed the expression filter. In
Condition B, RA for 8 h, 14,708 probe sets passed the
expression filter. In Condition C, RA for 72 h, 15,021 probe sets
passed the expression filter.Probe sets that passed the first filter were subjected to a
second filter that was based on a fold-change of at least 2
between Wt and CYP26A1−/− ES cells. In Condition A, Control
342 S. Langton, L.J. Gudas / Developmental Biology 315 (2008) 331–354for 8 h, 258 probe sets passed the fold-change filter. In
Condition B, RA for 8 h, 259 probe sets passed the fold-change
filter. In Condition C, RA for 72 h, 645 probe sets passed the
filter. Finally, these probe sets were subjected to statistical
analysis, and probe sets that had significantly different means
(log ratio) based on the Student's t-test (pb0.05) passed this last
filter and designated as differentially expressed transcripts.
A total of 165 transcripts were either up- or down-regulated
in Wt versus CYP26A1−/− ES cells by 2-fold or greater in
condition A, Control for 8 h (Table 1 lists the top 20 and bottom
20 transcripts. For the complete list, see Supplemental Table 1).
Of these 165 differentially expressed transcripts, 108 transcripts
were down-regulated in CYP26A1−/− ES cells compared to Wt.
Some of the genes differentially expressed in the absence of RATable 1
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Top 20 genes with at least 2-fold higher expression in WT ES cells relative to CYP2









































a Average from three experiments.
b Some genes have multiple distinct probes on the GeneChip® resulting in differe
c PrkWnk3 mRNA is expressed at a 97.16±32.75-fold higher level in control WT
d Fold change means ratio of Wt to CYP26A1−/− when CYP26A1−/− is set at 1 (einclude Bnip3, Epha4, Fcgr2b, Gja1, Igfbp3, LamB1, Leftb,
Pdk1, PrkWnk3, Stk2, and Trl2. It is of interest that we did not
observe any differences in Nanog, Oct3/4, or Sox2 mRNA
levels between the AB1 Wt and the Cyp26A1−/− ES cells
cultured without RA (control) and plus LIF, either in these
microarray experiments or in Northern analyses we performed
(data not shown).
A total of 183 transcripts were either up- or down-regulated
in Wt versus CYP26A1−/− ES cells by 2-fold or greater in
Condition B, RA for 8 h (Table 2 lists the top 20 and bottom 20
transcripts. For the complete list, see Supplemental Table 2). Of
these 183 differentially expressed transcripts, 136 transcripts
were down-regulated in CYP26A1−/− ES cells relative to Wt.
Among the differentially expressed genes in Condition B areGene title
6A1−/− cells after 8 h in control medium. All are +LIF (WT/CYP26A1−/−)
Protein kinase, lysine deficient 3
Mus musculus, clone IMAGE:4206343, mRNA
Mus musculus cDNA clone MGC:61032 IMAGE:30024827, complete cds
Rho, GDP dissociation inhibitor (GDI) beta
Palladin
Eph receptor A4
G elongation factor, mitochondrial 2
Fructose bisphosphatase 2
RIKEN cDNA 2410003B16 gene
Eph receptor A4
Bardet–Biedl syndrome 2 homolog (human)
Cyclin-dependent kinase inhibitor 1C (P57)
Ubiquitin-activating enzyme E1, Chr Y 1
Immunoglobulin-like domain containing receptor 1
Chloride channel calcium activated 4
Beta-2 microglobulin
Rhotekin
Scm-like with four mbt domains 2
Beta-2 microglobulin
Ubiquitin-activating enzyme E1, Chr Y 1
6A1−/− cells after 8 h in control medium. All are +LIF (WT/CYP26A1−/−)
Triosephosphate isomerase
Adducin 3 (gamma)
RIKEN cDNA 1810059G22 gene
CD38 antigen




Adenylate kinase 3 alpha-like
Adaptor protein complex AP-1, mu 2 subunit
Adenylate kinase 3 alpha-like
Choline kinase
Adenylate kinase 3 alpha-like
Crumbs homolog 3 (Drosophila)
Fc receptor, IgG, low affinity IIb
RAN binding protein 6
Histone 1, H1c
Histone 1, H2bc
BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3
Toll-like receptor 2
nt fold-changes from the different probes.
ES versus control CYP26A1−/− ES cells.
.g. 0.40 in Table 1—2.5 fold change).
Table 2
Affymetrix ID Fold change a, b, d Gene symbol Gene title
Top 20 genes with at least 2-fold higher expression in WT ES cells relative to CYP26A1−/− cells after RA treatment for 8 h. All are +LIF (WT/CYP26A1−/−)
1443924_at 79.57 Prkwnk3 c Protein kinase, lysine deficient 3
1429701_at 13.30 2410003J06Rik RIKEN cDNA 2410003J06 gene
1423523_at 12.87 Aass Aminoadipate-semialdehyde synthase
1448269_a_at 12.61 Bklhd2 BTB and kelch domain containing 2
1447021_at 11.06 – Mus musculus cDNA clone MGC:61032 IMAGE:30024827, complete cds
1436320_at 9.52 – Mus musculus, clone IMAGE:4206343, mRNA
1421928_at 8.74 Epha4 Eph receptor A4
1433768_at 7.04 Palld Palladin
1419430_at 6.06 Cyp26a1 Cytochrome P450, family 26, subfamily a, polypeptide 1
1449088_at 5.85 Fbp2 Fructose bisphosphatase 2
1442384_at 5.32 GFM2 G elongation factor, mitochondrial 2
1429021_at 4.72 Epha4 Eph receptor A4
1427228_at 4.67 2410003B16Rik RIKEN cDNA 2410003B16 gene
1449289_a_at 4.37 B2m Beta-2 microglobulin
1423276_at 4.18 Ildr1 Immunoglobulin-like domain-containing receptor 1
1434353_at 4.13 Sfmbt2 Scm-like with four mbt domains 2
1448804_at 4.02 Cyp11a1 Cytochrome P450, family 11, subfamily a, polypeptide 1
1454806_at 3.98 D12Ertd553e DNA segment, Chr 12, ERATO Doi 553, expressed
1436794_at 3.88 C330026N02Rik RIKEN cDNA C330026N02 gene
1427543_s_at 3.82 Ube1y1 Ubiquitin-activating enzyme E1, Chr Y 1
Top 20 genes with at least 2-fold lower expression in WT ES cells relative to CYP26A1−/− cells after RA treatment for 8 h. All are +LIF (WT/CYP26A1−/−)
1417967_at 0.44 Mms19l MMS19 (MET18 S. cerevisiae)-like
1436202_at 0.44 Pro1073 Pro1073 protein
1419031_at 0.43 Fads2 Fatty acid desaturase 2
1418049_at 0.43 Ltbp3 Latent transforming growth factor beta binding protein 3
1435659_a_at 0.42 Tpi Triosephosphate isomerase
1431815_a_at 0.42 Mms19l MMS19 (MET18 S. cerevisiae)-like
1450264_a_at 0.42 Chk Choline kinase
1456480_at 0.41 Fry Furry homolog (Drosophila)
1452142_at 0.41 Slc6a1 Solute carrier family 6 (neurotransmitter transporter, GABA), member 1
1418744_s_at 0.40 2410011K10Rik RIKEN cDNA 2410011K10 gene
1455220_at 0.39 Frat2 Frequently rearranged in advanced T-cell lymphomas 2
1432436_a_at 0.38 Ak3l Adenylate kinase 3 alpha-like
1419241_a_at 0.37 Aire Autoimmune regulator (autoimmune polyendocrinopathy candidiasis
ectodermal dystrophy)
1435192_at 0.36 Sox3 SRY-box containing gene 3
1435477_s_at 0.34 Fcgr2b Fc receptor, IgG, low affinity IIb
1436994_a_at 0.33 Hist1h1c Histone 1, H1c
1418072_at 0.32 Hist1h2bc Histone 1, H2bc
1422470_at 0.31 Bnip3 BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3
1451941_a_at 0.27 Fcgr2b Fc receptor, IgG, low affinity IIb
1419132_at 0.26 Tlr2 Toll-like receptor 2
a Average from three experiments.
b Some genes have multiple distinct probes on the GeneChip® resulting in different fold-changes from the different probes.
c PrkWnk3 mRNA is expressed at a 79.57±27.66-fold higher level in RA-treated WT ES versus RA-treated CYP26A1−/− ES cells.
d Fold change means ratio of Wt to CYP26A1−/− when CYP26A1−/− is set at 1 (e.g. 0.40 in Table 1—2.5 fold change).
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Sox3, and Trl2.
A total of 187 transcripts were either up- or down-regulated
in Wt versus CYP26A1−/− ES cells by 2-fold or greater in
Condition C, RA for 72 h (Table 3 lists the top 20 and bottom 20
transcripts. For the complete list, see Supplemental Table 3). Of
these 187 differentially expressed transcripts, 119 transcripts
were down-regulated in CYP26A1−/− ES cells relative to Wt.
Some of the differentially expressed genes in the presence of
RA for 72 h are Calponin, Caldesmon, Epha4, Hist1h1c,
Hist1h2bp, Hoxb4, Nrp1, Pmp22, Tagln, and Thbs1.
To validate the microarray data, new cell samples were used
to confirm the results. In addition to CYP26A1−/− #59, whichwas the cell line used for the microarray analyses, other inde-
pendently derived CYP26A1−/− ES cell lines, #142 and #165,
were tested during the validation studies. Several differentially
expressed genes were selected for examination by semi-
quantitative reverse transcription-polymerase chain reaction
(RT-PCR). As a loading control, RT-PCR of 36B4, a house-
keeping gene that encodes the acidic ribosomal protein P0, was
used for comparison.
For validation of genes differentially expressed in Condi-
tions A (Control for 8 h) and B (100 nM RA for 8 h), Wt and
CYP26A1−/− #59, #142, and #165 ES cells were treated with
control vehicle or 100 nM RA for 8 h. The five genes chosen for
validation of the 8-h time point by RT-PCR analyses were
Table 3
Affymetrix ID Fold change a, b, d Gene symbol Gene title
Top 20 genes with at least 2-fold higher expression in WT ES cells relative to CYP26A1−/− cells after RA treatment for 72 h. All are +LIF (WT/CYP26A1−/−)
1423505_at 56.91 Tagln c transgelin
1429701_at 48.31 2410003J06Rik RIKEN cDNA 2410003J06 gene
1434739_at 30.21 Frm1nb Fragile X mental retardation 1 neighbor
1427735_a_at 20.62 Acta1 Actin, alpha 1, skeletal muscle
1421811_at 19.57 Thbs1 Thrombospondin 1
1460330_at 19.46 Anxa3 Annexin A3
1452670_at 18.35 Myl9 Myosin, light polypeptide 9, regulatory
1436997_x_at 17.61 Sh3bgrl SH3-binding domain glutamic acid-rich protein like
1428107_at 16.26 Sh3bgrl SH3-binding domain glutamic acid-rich protein like
1426221_at 13.66 Loh11cr2a Loss of heterozygosity, 11, chromosomal region 2, gene A homolog (human)
1421871_at 12.85 Sh3bgrl SH3-binding domain glutamic acid-rich protein like
1448269_a_at 12.02 Bklhd2 BTB and kelch domain containing 2
1439810_s_at 11.86 Pramel7 Preferentially expressed antigen in melanoma like 7
1416242_at 10.56 Bklhd2 BTB and kelch domain containing 2
1424246_a_at 10.49 Tes Testis derived transcript
1438133_a_at 10.00 Cyr61 Cysteine rich protein 61
1417133_at 9.94 Pmp22 Peripheral myelin protein
1423824_at 9.71 Gpr177 G-coupled receptor 177
1448169_at 9.62 Krt1-18 Keratin complex 1, acidic, gene 18
1437434_a_at 9.52 Gpr177 G-coupled receptor 177
Top 20 genes with at least 2-fold lower expression in WT ES cells relative to CYP26A1−/− cells after RA treatment for 72 h. All are +LIF (WT/CYP26A1−/−)
1417725_a_at 0.39 Sssca1 Sjogren's syndrome/scleroderma autoantigen 1 homolog (human)
1451761_at 0.38 Hoxb4 Homeo box B4
1435783_at 0.38 – Mus musculus 12 days embryo spinal ganglion cDNA, RIKEN full-length
enriched library, clone: D130013O06 product: unknown EST, full insert sequence
1440867_at 0.36 Spry4 Sprouty homolog 4 (Drosophila)
1427762_x_at 0.36 Hist1h2bp Histone 1, H2bp
1435659_a_at 0.35 Tpi Triosephosphate isomerase
1448661_at 0.35 Plcb3 Phospholipase C, beta 3
1418536_at 0.35 H2–Q7 Histocompatibility 2, Q region locus 7
1455516_at 0.33 A330102K23Rik RIKEN cDNA A330102K23 gene
1423748_at 0.33 Pdk1 Pyruvate dehydrogenase kinase, isoenzyme
1447946_at 0.32 AW046396 Expressed sequence AW046396
1418373_at 0.32 Pgam2 Phosphoglycerate mutase 2
1440074_at 0.28 – Mus musculus ES cells cDNA, RIKEN full-length enriched library, clone:
C330036H15 product: hypothetical Cysteine-rich region containing protein,
full insert sequence
1435457_at 0.27 Pdzd4 PDZ domain-containing 4
1452540_a_at 0.27 Hist1h2bp Histone 1, H2bp
1436994_a_at 0.20 Hist1h1c Histone 1, H1c
1449005_at 0.18 Slc16a3 Solute carrier family 16 (monocarboxylic acid transporters), member 3
1418072_at 0.16 Hist1h2bc Histone 1, H2bc
1418677_at 0.16 Actn3 Actinin alpha 3
1416101_a_at 0.15 Hist1h1c Histone 1, H1c
a Average from two experiments.
b Some genes have multiple distinct probes on the GeneChip® resulting in different fold-changes from the different probes.
c Tagln mRNA is expressed at a 56.91±17.76-fold higher level in RA-treated WT ES versus RA-treated CYP26A1−/− ES cells.
d Fold change means ratio of Wt to CYP26A1−/− when CYP26A1−/− is set at 1 (e.g. 0.40 in Table 1 — 2.5 fold change).
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genes were selected for validation because they had relatively
high fold-changes and/or were found to have interesting
biological functions.
Epha4 belongs to the ephrin receptor subfamily of the
protein–tyrosine kinase family and has been shown to play
roles in axonal guidance signaling and segmentation of the
hindbrain during development (Holmberg and Frisen, 2002;
Nittenberg et al., 1997). Epha4 mRNA levels were 5.1±
1.8-fold and 8.7±3.1-fold lower in CYP26A1−/− ES cells
than in Wt ES cells in both Conditions A and B, respect-ively, and semi-quantitative RT-PCR confirmed that Epha4
expression was higher in Wt than in CYP26A1−/− ES cells
(Fig. 8A). Epha4 mRNA levels were also 3.6±0.6-fold
higher in Wt ES cells than in CYP26A1−/− ES cells in
Condition C, and this was confirmed by semi-quantitative
RT-PCR (Figs. 8C, D).
PrkWnk3 (also known as WNK3) is a member of the “with
no lysine” (WNK) serine–threonine protein kinase family that
activates Na–(K)–Cl transporters by increasing their phosphor-
ylation (Kahle et al., 2005). PrkWnk3 was shown to interact
with procaspase 3 and heat shock protein 70 to increase cell
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mRNA levels were higher in Wt than in CYP26A1−/− ES cells
by 97.2±32.8-fold in Condition A and by 79.6±27.6-fold in
Condition B, and semi-quantitative RT-PCR confirmed that
PrkWnk3 mRNA levels are higher in Wt ES cells than in
CYP26A1−/− ES cells (Figs. 8C, D).
Aminoadipate-semialdehyde synthase (Aass) encodes a
bifunctional enzyme that catalyzes the conversion of lysine to
alpha-aminoadipic semialdehyde in the mammalian lysine
degradation pathway (Markovitz and Chuang, 1987; Sacksteder
et al., 2000). AassmRNAwas higher inWt than in CYP26A1−/−
ES cells by 12.8±6.9-fold in the Condition B, and semi-
quantitative RT-PCR validated this (Fig. 8A).
LamB1 mRNA expression has been shown to be tran-
scriptionally regulated by RA by our laboratory (Li and Gudas,
1996, 1997; Sharif et al., 2001; Vasios et al., 1991). LamB1
mRNA levels in Wt were 2.7±0.6-fold higher than in
CYP26A1−/− ES cells in Condition A and 3.5±1.3-fold higher
in Wt ES cells in Condition B, consistent with our prior data
(Figs. 5 and 8A).
Latent transforming growth factor beta binding protein 3
(Ltbp3) has been shown to bind transforming growth factor β
(TGFβ) and to play a role in cell growth and skeletal
development (Dabovic et al., 2005). Ltbp3 mRNA levels were
2.4 ± 0.3-fold lower in Wt ES cells as compared to
CYP26A1−/− ES cells in Condition B, and semi-quantitative
RT-PCR confirmed that Ltbp3 mRNA levels are higher in
CYP26A1−/− ES cells than in Wt ES cells (Fig. 8A).
For validation of genes differentially expressed in Condition
C (100 nM RA for 72 h), Wt and CYP26A1−/− #59 and #142
ES cells were treated with varying concentrations of RA for
72 h. For validation of the 72-h time point, semi-quantitative
RT-PCR analyses of Epha4, Tagln, and Pmp22 were performed
(Fig. 8B).
Transgelin (Tagln), also known as Smooth muscle α22 is
expressed in smooth muscle cells and fibroblasts (Lawson et al.,
1997). Tagln mRNA levels were 56.9±17.7-fold higher in Wt
ES cells than in CYP26A1−/− ES cells in Condition C, and this
was validated by semi-quantitative RT-PCR (Figs. 8C, D).
The Peripheral myelin protein 22 (Pmp22) gene encodes a
glycoprotein that is a major component of myelin in the
peripheral nervous system (Amici et al., 2006), and Pmp22
complexes with extracellular matrix molecules to mediate
interactions of glial cells with the extracellular environment
(Amici et al., 2006). Pmp22 mRNA levels were 9.9±1.9-fold
higher in Wt ES cells than in CYP26A1−/− ES cells in
Condition C, and semi-quantitative RT-PCR confirmed that
Pmp22mRNA levels are lower in CYP26A1−/− ES cells than in
Wt ES cells (Figs. 8C, D).
Functional analyses of differentially expressed genes by Gene
Ontology classification
Assigning biological functions to the differentially regulated
genes is a first step in understanding how Wt ES cells and
CYP26A1−/− ES cells are functionally different from each
other. The Gene Ontology (GO) Consortium developed threestructured, controlled vocabularies (ontologies) that describe
the gene products in terms of their associated biological
processes, molecular functions, and cellular components in a
species-independent manner (Ashburner et al., 2000). Biologi-
cal processes include broad biological goals that are based on
multi-step molecular functions, such as metabolism, cell
differentiation, and transcription. Molecular functions describe
the activities performed by the individual gene product and
include such functions as kinase activity and ion binding.
Cellular components are the physical locations of the gene
product, such as nucleus and cytoskeleton. For the purpose of
understanding how the loss of Cyp26a1 affects the biology of
ES cells, we chose to identify the biological processes
associated with genes that show reduced or increased expres-
sion independently.
DAVID, which stands for Database for Annotation,
Visualization, and Integrated Discovery, is a web-based tool
that analyzes and annotates genome-scale data sets based on
GO terms and identifies categories that are over-represented in
the gene list relative to the representation within the genome of
a given species. First, the functional annotation clustering tool
displays similar annotations together in clusters. The grouping
algorithm is based on the hypothesis that similar annotations
should have similar gene members. The degree of common
genes between two annotations is measured by Kappa
statistics, and the Kappa values are then used to classify
groups of similar annotations. Next, DAVID calculates the
chances of over-representation of the clusters using the Fisher
Exact test. The main benefit of over-representation analysis is
to order categories associated with a gene list in order to focus
on those processes most likely associated with the biological
phenomenon under study; in this case, the biological
phenomenon is the lack of CYP26A1 enzyme activity in ES
cells.
Based on the genes that were expressed at higher levels in the
CYP26A1−/− ES cells relative to Wt ES cells, the biological
processes termed DNA metabolism and chromosome organiza-
tion were the top GO terms to be enriched in all conditions
(Table 4 and Fig. 9). Five histone genes were expressed at
higher mRNA levels in CYP26A1−/− ES cells than in Wt ES
cells, including Hist1h2bf, Hist1h2bc, Hist1h2bp, Hist1h1c,
and Hist1h3c1.
In Conditions A and B, Wt ES cells were highly enriched
for genes involved in cell proliferation and cellular morpho-
genesis, such as Igfbp3, Gja1, and Leftb, suggesting that
CYP26A1 activity is important for normal ES cell prolifera-
tion and morphogenesis (Table 4). Igfbp3 binds IGF (Insulin-
like growth factor) to inhibit IGF activity, which stimulates
cell proliferation and differentiation (Ranke and Elmlinger,
1997). Igfbp3 has also been shown to bind RXR, resulting in
reduced RAR signaling (Liu et al., 2000). Leftb (also known
as Lefty) is a direct transcriptional target of Oct-4, and is
expressed in pluripotent ES cells (Babaie et al., 2007;
Tabibzadeh and Hemmati-Brivanlou, 2006). Leftb encodes a
protein that is a member of the TGFβ family and plays a role
in maintaining pluripotency in ES cells (Tabibzadeh and
Hemmati-Brivanlou, 2006). Gja1 encodes a gap junction
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human ES cells, and is involved in signal transduction
(Bhattacharya et al., 2004; Player et al., 2006).In Conditions A and B, CYP26A1−/− ES cells relative to Wt
ES cells were highly enriched for genes involved in stress
response and defense response, suggesting that CYP26A1
Fig. 8. Semi-quantitative RT-PCR analyses of selected genes, Epha4, PrkWnk3, Aass, LamB1, Ltbp3, Tagln, and Pmp22 for validation of microarray results at the 8-h or
72-h RA treatment time point. A representative experiment for each gene is shown. A housekeeping gene, 36B4, was used as an internal control. Serial dilutions were
performed to show that the PCR was in the linear range and not saturated. (A) AB1 WT, CYP26A1−/− #59, #142, and #165 ES cells were treated with 100 nM RA or
control vehicle for 8 h. A sample without reverse transcription (−rt) was used as a negative control in the PCR reactions. (Even though Epha4 is shown without the −rt
lane, repeated independent experiments indicated no pcr product for Epha4 in the −rt condition.) Lane 1 shows the DNA ladder, except in the Ltbp3 sample. The
experiments shown in all panels were repeated three times with different RNA preparations and similar results were obtained. (B) Densitometry analyses of the semi-
quantitative RT-PCR of the genes in panel A are shown in the bar graphs. The y-axis is the density value of the RT-PCR signal as calculated using Alpha Innotech
Fluorchem software program (San Leandro, CA). The density values of 36B4 RNA are also shown for comparison. (C) AB1 WT, CYP26A1−/− #59, and #142 ES cells
were treated with varying concentrations of RA (10–1000 nM) or with control vehicle for 72 h. A sample without reverse transcription (−rt) was used as a negative
control. These experiments were repeated twice with different RNA preparations and similar results were obtained. (D) Densitometry analyses of the semi-quantitative RT-
PCR of the genes in (C) are shown in the bar graphs. The y-axis is the density value of the RT-PCR signal as calculated using Alpha Innotech Fluorchem software program.
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response to stress in ES cells (Fig. 9). The stress response-
related genes that displayed higher mRNA levels in CYP26A−/−
ES cells than in Wt ES cells included Tlr2, Stk2 Fcgr2b, Bnip3,
and Pdk1. Tlr2 was found to have the largest positive fold-
change in CYP26A1−/− ES cells versus Wt ES cells in both the
absence and presence of RA for 8 h (Conditions A and B).Serine/threonine kinase 2 (Stk2), also known as ste20-like
kinase (slk), is involved in caspase-dependent apoptosis induced
by various stress stimuli (Sabourin et al., 2000). Fcgr2b is the
only known immunoglobulin G receptor capable of inducing
apoptosis, which was shown in B-cells to involve pro-apoptotic
Bcl-2 members Bid and Bad (Carter and Harnett, 2004). Bnip3
expression is regulated by hypoxia-inducible factor-1α (HIF-
Table 4
Biological processes that are enriched in WT ES cells or CYP26A1−/− ES cells,
in each condition
Condition WT ES cells CYP26A1−/− ES cells
A. 8-h Control Cell proliferation Chromatin assembly
Cell morphogenesis DNA metabolism
Response to stress
Defense response
B. 8-h RA Cell proliferation Chromatin assembly
Cell morphogenesis DNA metabolism
Response to stress
Defense response
C. 72-h RA Cell differentiation Chromatin assembly
Nervous system development DNA metabolism
Vasculature development
Angiogenesis
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a role in hypoxia-induced cell death (Guo et al., 2001; Lee and
Paik, 2006). Pyruvate dehydrogenase kinase 1 (Pdk1) is also
induced by HIF-1α as a cellular response to hypoxia, resulting
in reduced mitochondrial function and oxygen consumption
(Kim et al., 2006; Papandreou et al., 2006). The increased
expression of these genes in CYP26A1−/− ES cells indicates
that the lack of CYP26A1 function results in increased cellular
stress, even in the absence of RA. A previous study showed that
retinol levels above the physiological limit resulted in oxidative
stress and apoptosis in human dermal fibroblasts (Gimeno et al.,
2004). It is possible that, in the absence of RA, basal levels ofFig. 9. Proposed model for the actions of CYP26A1 in ES cells. In this model, RA acts
of CYP26A1 is to metabolize RA into polar RA metabolites, such as 4-oxo-RA
transcription of endodermal markers, neuronal markers, and smooth muscle cell-rela
genes is reduced, resulting in altered cell differentiation and/or development. Moreo
CYP26A1−/− ES cells, the lack of CYP26A1 leads to increased sensitivity of ES cells
compared.CYP26A1 protein in Wt ES cells metabolize retinol to maintain
precise levels that do not elicit the stress response, while the
lack of CYP26A1 basal activity in CYP26A1−/− ES cells results
in high retinol levels that do elicit the stress response.
In Condition C, genes up-regulated in Wt ES cells relative to
CYP26A1−/− ES cells were found to be enriched in the
biological processes, cell differentiation, nervous system devel-
opment, vasculature development, and angiogenesis categories,
which indicates that Wt ES cells are induced by RA to
differentiate into certain cell lineages, and that these develop-
mental programs require CYP26A1 activity to proceed normally
(Table 4 and Fig. 9). Some of the differentiation-related genes
expressed at higher levels in Wt versus CYP26A1−/− ES cells
were Tagln,Calponin, Epha4, Pmp22, andNrp1. The functional
annotation analysis results indicate that with the addition of RA
for 72 h, Wt ES cells adopt specific characteristics of
differentiating cells. However, differentiation appears to be
more limited in CYP26A1−/− ES cells relative to Wt ES cells.
Discussion
Lack of RA metabolism and reduced differentiation in the
CYP26A1−/− ES cell lines
Here we report the generation and characterization of cultured
murine ES cells with a targeted disruption of both alleles of
Cyp26a1. This method was chosen for several reasons. First,
the targeting construct had been used to generate Cyp26a1-nullthrough RXR:RAR to induce cell growth arrest and cell differentiation. The role
, and this activity promotes cell differentiation and maturation by activating
ted genes. In the absence of CYP26A1, the expression of differentiation-related
ver, as indicated by the increased expression of stress-response-related genes in
to stress. The bold print indicates higher mRNA levels when the two cell lines are
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recombination process ensures that no expression of Cyp26a1
will occur. Other methods to reduce gene expression, such as
RNA-interference and antisense technology, often result in some
expression of the target gene, as well as induction of non-specific
pathways (off target effects) (Houdebine, 2002; Marques and
Williams, 2005; Sledz and Williams, 2005). The phenotype of
the CYP26A1−/− mouse indicates that the areas in which
CYP26A1 is normally expressed developmorphogenetic defects
(Abu-Abed et al., 2001; Sakai et al., 2001). For example,
CYP26A1−/− mouse embryos show abnormal patterning of the
hindbrain and posterior transformation of the cervical vertebrae
(Abu-Abed et al., 2001; Sakai et al., 2001). These areas most
likely have increased RA levels resulting from the lack of
CYP26A1 activity. Deletion of one copy of retinaldehyde
dehydrogenase-2 (RALDH2) in CYP26A1−/− mice rescued
many of the defects attributable to the lack of CYP26A1, and the
authors speculated that this resulted from the reduction of RA
levels to a range that is compatible with proper embryonic
development (Niederreither et al., 2002). In the present study we
show that disruption of both copies of Cyp26a1 in ES cells
resulted in increased intracellular RA levels (Fig. 2), but
decreased differentiation, as assessed by parietal endoderm-
related gene expression (Fig. 5), by neuronal differentiation gene
expression (Figs. 8 and 9, and Table 4), and by smooth muscle
cell differentiation gene expression (Figs. 8 and 9, and Table 4).
The role of CYP26A1 inmetabolizing RA is not limited to the
embryo since CYP26A1 is also expressed in various adult
tissues, including brain, spleen, lung, liver, skeletal muscle, and
testis (Choudhary et al., 2003; White et al., 1997). CYP26A1 is
involved in retinoid signaling in the endometrium, as it is
transcriptionally activated by progesterone in mice and by
estrogen in humans (Fritzsche et al., 2007). CYP26A1 is also a
gene target for cancer treatment because of its role in
metabolizing RA and decreasing the sensitivity of various
cancer cells to RA-induced differentiation or apoptosis (Arm-
strong et al., 2005; Klaassen et al., 2001; Ozpolat et al., 2005).
Recently, Shelton et al. (2006) discovered that the CYP26A1
protein is up-regulated by a Wnt-dependent mechanism in
tissues deficient in the colon tumor suppressor gene, adenoma-
tous polyposis coli (APC), in zebrafish, mice, and humans. Their
findings suggest that APC promotes intestinal cell differentia-
tion in part by suppressing the catabolism of RA by CYP26A1
(Shelton et al., 2006). In acute promyelocytic leukemia (APL)
cells,Cyp26a1 gene transcription was enhanced by Hoxa10v2, a
homeobox transcription factor, after all-trans-RA treatment
(Quere et al., 2007). Highly RA-sensitive APL blasts expressed
higher levels of Cyp26a1 compared to low RA-sensitive APL
blasts (Quere et al., 2007). Collectively, these data show that RA
metabolism and signaling play important roles in differentiation
and cancer progression.
The use of liarozole or ketoconazole, both broad-spectrum
cytochrome P450 inhibitors, to inhibit RA metabolism in
various normal and cancer cell lines also resulted in increased
intracellular RA levels (Sonneveld et al., 1999b). Recently,
newer, more specific inhibitors of CYP26s, including the highly
CYP26-specific R116010 compound, have been described(Armstrong et al., 2005; Njar et al., 2006; Van Heusden et al.,
2002). One major limitation of general cytochrome P450
inhibitors is that they inhibit many or all CYPs, whereas our
study targeted only Cyp26a1 and is therefore more specific to
RA metabolism. Our results demonstrate that the disruption of
this single gene results in increased intracellular RA, but in
decreased sensitivity to growth inhibition by RA (Fig. 3).
Previously, our lab showed that the removal of LIF resulted
in the increased differentiation and metabolism of retinol to 4-
oxo-retinol in murine CCE ES cells without the addition of
exogenous RA (Lane et al., 1999, 2008). Induction of Cyp26a1
mRNA was correlated with the conversion of retinol to 4-oxo-
retinol, suggesting that Cyp26a1 was responsible for the
increased metabolism (Lane et al., 1999). We show here that
the absence of LIF also increased retinoid metabolism in murine
AB1 ES cells and that this effect was observed in both Wt and
CYP26A1−/− ES cells (Fig. 2). More polar RA metabolites were
detected in the samples without LIF than with LIF at the 8- and
24-h time points for Wt ES cells, and at the 24- and 48-h time
points for CYP26A1−/− ES cells. These data suggest that LIF
removal results in increased RA metabolism at later times
(N48 h) that is independent of CYP26A1 function in AB1 ES
cells. The removal of LIF could be associated with increased
retinoid uptake, increased metabolic enzyme activity, increased
CYP26B1 or CYP26C1 activity, or decreased efflux of RA.
Recently, the identification of Stra6 as the receptor for the serum
retinol binding protein (RBP4) indicates that an active transport
system for retinol exists, at least in some cell types (Kawaguchi
et al., 2007).
CYP26A1−/− ES cells are more resistant to RA-induced growth
arrest
The molecular mechanisms involved in the anti-proliferative
properties of RA have been shown to include both cell cycle
arrest and apoptosis in tumor cell lines (Mongan and Gudas,
2007), but the mechanism by which RA inhibits growth in cells
of embryonic origin remains unclear (Faria et al., 1999; Huynh
et al., 2006; Osanai and Petkovich, 2005; Walkley et al., 2004).
We have shown previously that in F9 EC cells, signaling
through RARβ2 is required, since RARβ2 knockout cells
exhibited no growth arrest in response to RA (Faria et al., 1999).
RARβ2 mRNA levels, examined by semi-quantitative RT-PCR,
were similar in both Wt and CYP26A1−/− ES cells (data not
shown). In addition, RA-induced growth arrest of F9 EC cells is
associated with up-regulation of p27 protein and down-
regulation of cyclin D1, D3, and E proteins (Li et al., 2004b).
Despite higher intracellular RA levels, CYP26A1−/− ES cell
were more resistant to RA-induced growth inhibition than Wt
ES cells (Fig. 3). Polar RA and ROL metabolites have been
shown to inhibit the proliferation of various cell types (Faria et
al., 1998; Idres et al., 2001; van der Leede et al., 1997), so we
speculate that their presence enhances ES cell growth arrest by
RA. 4-oxo-RA has been shown to bind and transactivate RARα
more efficiently than all-trans-RA (Idres et al., 2002), so the
presence of 4-oxo-RA in Wt ES cells may heighten the growth
arrest response of RA by acting through the RARα isoform.
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analyses, were similar between Wt and CYP26A1−/− ES cells
(data not shown).
Newer CYP inhibitors have been generated and shown to
inhibit RA metabolism specifically, as well as to exert retinoidal
effects (Njar et al., 2006; Patel et al., 2004). Recently, studies
with a second generation RAMBA, R116010, showed that a
combination of R116010 and RA increased intracellular levels
of RA in neuroblastoma cell lines by at least 2-fold, but the
growth inhibitory effects of RA were enhanced by only a
modest 11% when combined with R116010 (Armstrong et al.,
2005). These results demonstrate that specific inhibition of
CYP26A1, either by removal of the gene in our case or by
inhibiting activity with R116010 (Armstrong et al., 2005), leads
to increased intracellular RA levels, but that this increase does
not result in a concomitant increase in growth inhibition. Thus,
the effect of RA on growth inhibition is not as simple as
previously believed, and the assumption that a higher internal
concentration of RA equals more growth inhibition is not true in
the CYP26A1−/− versus Wt ES cells.
The early-response, direct RA target gene, Hoxa1, is induced to
a higher level in CYP26A1−/− ES cells
Hoxa1 gene is a direct, transcriptional RA target gene with a
classical DR5 RARE in its regulatory region (Langston and
Gudas, 1992; Langston et al., 1997). The high affinity RARE is
very sensitive to retinoids and acts as a “direct readout” of
intracellular RA concentration in ES cells (Dupe et al., 1997;
Langston and Gudas, 1992). Ectopic Hoxa1 expression driven
by a β-actin promoter in mice results in major developmental
defects, including embryonic lethality (Zhang et al., 1994).
Interestingly, as in CYP26A1−/− mice, rhombomeres of the
developing hindbrain are transformed in mouse embryos with
ectopic Hoxa1 expression (Abu-Abed et al., 2001; Sakai et al.,
2001; Zhang et al., 1994). Specifically, rhombomeres 2 and 3
are transformed into a rhombomere-4-like identity, and this
defect is seen in both CYP26A1−/− mice and mice with ectopic
Hoxa1 expression. Previous studies from our laboratory showed
that overexpression of ectopic Hoxa1 affected a wide range of
genes, including genes encoding enzymes, growth factors,
chromatin and cell cycle regulatory proteins, and other home-
odomain-containing proteins (Shen et al., 2000). In this study,
CYP26A1−/− ES cells exhibited higher levels of Hoxa1 mRNA
than Wt ES cells after RA treatment (Fig. 4), indicating that the
loss of CYP26A1 activity leads to an increase in retinoid
signaling, including increased Hoxa1 transcriptional activation.
These data indicate that the appropriate level of Hoxa1 is
critical for normal embryonic development and that CYP26A1
can function to regulate Hoxa1 transcription by controlling the
levels of intracellular RA.
Parietal endoderm differentiation is reduced in CYP26A1−/−
ES cells
LamB1, J31 (also known as SPARC), and J6 encode proteins
involved in organizing the extracellular matrix and assemblingthe basement membrane, which occurs during parietal endo-
dermal differentiation (Brekken and Sage, 2001; Ekblom et al.,
2003; Leivo and Wartiovaara, 1989; Li et al., 2004a). These
RA-inducible, late-response genes are induced by RA with
maximal expression around 48 to 72 h (Wang and Gudas, 1988;
Wang et al., 1985). How RA metabolism plays a role in the
transcriptional regulation of these genes remains unclear. To
explain why these genes require a longer time to reach maximal
induction by RA, we hypothesized that these late-response
genes may require RA metabolism into polar RA metabolites
for transcriptional activation (Fig. 9). While we observe reduced
levels of expression of LamB1, J31, and J6 mRNA in
CYP26A1−/− ES cells compared to Wt ES cells, treatment
with the polar RA metabolite, 4-oxo-RA, did not restore the
expression of these genes to that found in Wt ES cells (Figs. 5
and 6). However, a caveat is that exogenously added 4-oxo-RA
and RA may differ from each other in terms of cellular uptake.
In addition, we cannot rule out the possibility that other polar
RA metabolites, such as 4-OH-RA, are involved in the
regulation of transcription of these RA-inducible late-response
genes. The possibility that CYP26A1 metabolizes a non-
retinoid that affects the expression of these “late” genes exists,
even though there is no evidence for this. The reduced mRNA
levels of these and other parietal endoderm-related genes in
CYP26A1−/− ES cells indicate that CYP26A1 activity is
required for proper endodermal differentiation. Lastly, some
of the differences noted may reflect differences between the Wt
parental ES cells and the Cyp26a1 knockout/knockout cells,
and thus may not be due to inactivation of the Cyp26a1 gene.
We did not examine the mRNA levels of all of the genes in the
Cyp26a1 knockout/knockout cells, but rather compared the Wt
ES cells with the Cyp26a1−/− lines in our analyses.
CYP26A1−/− ES cells express lower levels of genes involved in
smooth muscle cell differentiation and migration
Major progress has been made to differentiate embryonic
and adult stem cells into smooth muscle cells, but the exact
factors involved are still unclear (Owens et al., 2004). RA has
been shown to induce smooth muscle cell differentiation in
P19 EC cells (Blank et al., 1995), murine ES cells (Drab et al.,
1997), and human ES cells (Huang et al., 2006). The mRNA
levels of Madh3, Nrp1, Tagln, calponin2, and caldesmon1
were lower in CYP26A1−/− ES cells than in Wt ES cells
treated with RA for 72 h (Figs. 8 and 9, Table 3). Madh3, also
known as Smad3, is an effector molecule of TGFβ signaling
that acts as a transcription factor to mediate biological effects
of TFGβ, which include differentiation of smooth muscle cells
from ES cells (Kretschmer et al., 2003; Sinha et al., 2004).
Neuropilin 1 (Nrp1) is a vascular endothelial growth factor
(VEGF) receptor that is expressed in smooth muscle cells
(Ishida et al., 2001). Calponin2 is important for migration of
endothelial cells and for proper vascular development (Tang et
al., 2006). Taken together, the down-regulation of these genes
indicates that the lack of CYP26A1 may have a negative
influence on smooth muscle cell differentiation and/or
endothelial cell migration.
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neuronal cells
Epha4, Nrp, Pmp22, Gap43, and Ndn are other genes
involved in nervous system development that we found to be
down-regulated in CYP26A1−/− ES cells relative to Wt ES cells
treated with RA for 72 h (Figs. 8 and 9, and Table 3). Epha4
expression has been shown to be regulated by Krox-20, which is
a transcription factor crucial for proper hindbrain patterning
(Theil et al., 1998). Besides acting as a VEGF receptor to induce
smooth muscle cell growth, Nrp also plays an important role in
axon guidance by interacting with class 3 semaphorins (Van
Vactor and Lorenz, 1999). Another gene that plays a role in
nervous system development, but which we found to be up-
regulated in CYP26A1−/− ES cells, was Hoxb4. We found
increased expression of Hoxb4 in CYP26A1−/− ES cells treated
with RA for 72 h, which was in agreement with a previous
finding that Hoxb4 expression in the Cyp26a1-null mouse
embryo was increased and had expanded beyond its normal
boundaries in the somites (Sakai et al., 2001). Taken together,
the aberrant expression of these neural-associated genes in
CYP26A1−/− ES cells suggests that RA metabolism by
CYP26A1 is necessary for proper differentiation of ES cells
into neurons.
CYP26A1−/− ES cells express higher levels of genes involved in
DNA metabolism and chromosome organization
The expression of histones is tightly coupled to DNA
replication and mainly occurs during the S-phase of the cell
cycle (Marzluff and Duronio, 2002). The correct stoichio-
metric amounts of core histones are necessary for proper
nucleosome formation and chromosome function (Marzluff
and Duronio, 2002). Inappropriate ratios of histone proteins
can result in increased frequency of chromosome loss
(Meeks-Wagner and Hartwell, 1986). Deletion of the
Cyp26a1 gene resulted in greater than 2-fold increased
expression of various histone genes, including Hist1h2bf,
Hist1h2bc, Hist1h2bp, Hist1h1c, and Hist1h3c1, in all three
conditions, A, B, and C, suggesting that CYP26A1 activity
may be involved in replication-dependent gene transcription
or regulation of the cell cycle (Fig. 9, Tables 1–4). Fen1
and Nxf1 were also expressed 2.0 and 2.1-fold higher,
respectively, in CYP26A1−/− ES cells relative to Wt ES
cells. Fen1 is responsible for removing Okazaki DNA–RNA
flaps and for repairing DNA mismatches during DNA
synthesis (Kao and Bambara, 2003; Kim et al., 1998;
Stewart et al., 2006)). Nxf1 encodes Nuclear RNA export
factor 1, which mediates the general cellular export of
mRNA from the nucleus for translation of the mRNA into
protein (Erkmann and Kutay, 2004). Further analysis of
CYP26A1−/− ES cells, cultured in the absence of RA, is
warranted to determine the relationship between CYP26A1
activity and DNA synthesis. Our current hypothesis is that
retinol in the serum may play a role in these differences in
gene expression in the Cyp26a1−/− cells cultured without
added RA, but this has not been tested.Biological implications of the inhibition of RA metabolism in
murine ES cells by the disruption of CYP26A1
The ability of ES cells to self-renew and differentiate into
cells of all three germ layers makes ES cells a tool of great
potential in the study of developmental biology as well as in the
study of cell differentiation. Our microarray data suggest that
CYP26A1 activity is involved in at least three differentiation
programs in ES cells: parietal endoderm, smooth muscle, and
neural differentiation (Fig. 9).
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